ALFA Finder
21:12 IST
NSE
Earnings Call
Lupin Earnings Call Transcript: Key Takeaways
Revenue up 11% to ₹7,827 Cr, but EBITA margin fell to 25.1% from 31.3%; US down 13.4% QoQ on Tolvaptan erosion; management hedged FY28 outlook.
Lupin Ltd
Lupin Ltd news stories on ALFA NewsRead the news →- Share price
- ₹2,023.40
- Market cap
- ₹92,529 Cr
- Revenue (annual)
- ₹27,958 Cr
- Net profit (annual)
- ₹5,333 Cr
- P/E (TTM)
- 17.8×Sector 43.8×
- Promoter holding
- 46.84%-0.01% QoQ
- FII holding
- 23.28%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
All
Regulatory Approval 11Other Announcement 7Employee Stock Options 6Earnings Call 5Product Launch 4Business Update 4Merger & Restructuring 3Management Change 3Financial Results 3Annual General Meeting 3Partnership 2Board Meeting Date 2
Time
5 announcements with these filters
01:49 IST
NSE
Earnings Call
Lupin Investor Presentation: Key Takeaways
Q2 FY27 net sales ₹77,855mn (+14% YoY); EBITDA ₹19,574mn, margin 25.1% (vs 31.3%); net income ₹11,553mn (-21.8% YoY). US pressured by competition/LOE.
21:30 IST
BSE
Earnings Call
Lupin Earnings Call Transcript: Key Takeaways
Lupin reported record Q1 FY27 revenues of ₹8,277 crore with strong EBITDA margins of 30%. Growth was broad-based across US and India, though management expects near-term US moderation due to increased competition in key products.
22:12 IST
NSE
Earnings Call
Lupin Investor Presentation: Key Takeaways
Lupin delivered strong Q1 FY27 results with 33% YoY revenue growth and healthy 30% EBITDA margins, driven by outperformance in US and India markets.
17:09 IST
NSE
Earnings Call
Lupin Earnings Call: Key Takeaways
Lupin reported record FY26 revenues of ₹27,958 cr (up 23%) and EBITDA of ₹8,160 cr (up 55%). Management focuses on complex products and India prescription growth.